Syndax Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Syndax Pharmaceuticals has a total shareholder equity of $366.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $425.8M and $59.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$406.40m |
| Equity | US$366.43m |
| Total liabilities | US$59.38m |
| Total assets | US$425.81m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1T3's short term assets ($414.8M) exceed its short term liabilities ($59.4M).
Long Term Liabilities: 1T3's short term assets ($414.8M) exceed its long term liabilities ($2.0K).
Debt to Equity History and Analysis
Debt Level: 1T3 is debt free.
Reducing Debt: 1T3 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1T3 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1T3 has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 26.2% each year.